The possible roles of inhibitors, promoters, and macromolecules in the formation of calcium kidney stones

Urinary Tract Stone Disease

Volumn , Issue , 2011, Pages 31-60

  Ryall, Rosemary Lyons ^a  

^a FLINDERS UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84858440956     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-84800-362-0_4     Document Type: Chapter

References (379)

1. Kok DJ. Inhibitors of calcium oxalate crystallization. In: Khan SR, ed. Calcium Oxalate in Biological Systems. Boca Raton, New York, London, Tokyo: CRC; 1995:23-36.
2. Kavanagh JP. Supersaturation and renal precipitation: the key to stone formation? Urol Res. 2006;34:81-85.
3. Kok DJ. Clinical implications of physicochemistry of stone formation. Endocrinol Metabl Clin North Am. 2003;31:855-867.
4. Kok DJ, Papapoulos SE. Physicochemical considerations in the development and prevention of calcium oxalate urolithiasis. Bone Miner. 1993;20:1-15.
5. Robertson WG, Peacock M. Calcium oxalate crystalluria and inhibitors of crystallisation in recurrent renal stone-formers. Clin Sci. 1972;43:499-506.
6. Finlayon B, Reid F. The expectation of free and fixed particles in urinary stone disease. Invest Urol. 1978;15:442-448.
7. Kok DJ, Khan SR. Calcium oxalate nephrolithiasis, a free or fixed particle disease. Kidney Int. 1994;46:847-854.
8. Saw NK, Chow K, Rao PN, Kavanagh JP. Effects of inositol hexaphosphate (phytate) on calcium binding, calcium oxalate crystallization and in vitro stone growth. J Urol. 2007;177:2366-2370.
9. Lieske JC, Toback FG, Deganello S. Direct nucleation of calcium oxalate dihydrate crystals onto the surface of living renal epithelial cells in culture. Kidney Int. 1998;54:796-803.
10. Bigelow MW, Wiessner JH, Kleinman JG, Mandel NS. Calcium oxalate crystal attachment to cultured kidney epithelial cell lines. J Urol. 1998;160:1528-1532.
11. Lieske JC, Swift H, Martin T, Patterson B, Toback GF. Renal epithelial cells rapidly bind and internalize calcium oxalate monohydrate crystals. PNAS. 1994;91:6987-6991.
12. Lieske JC, Norris R, Swift H, Toback FG. Adhesion, internalization and metabolism of calcium oxalate monohydrate crystals by renal epithelial cells. Kidney Int. 1997;52:1291-1301.
13. Lieske JC, Huang E, Toback GF. Regulation of renal epithelial cell affinity for calcium oxalate crystals. Am J Physiol Renal Physiol. 2000;278:F130-F137.
14. Riese RJ, Riese JW, Kleinman JG, Wiessner JH, Mandel GS, Mandel NS. Specificity in calcium oxalate adherence to papillary epithelial cells in cultures. Am J Physiol. 1988;255:F1025-1032.
15. Verkoelen CF, Van der Boom BG, Kok DJ, Schroder FH, Romijn JC. Attachment sites for particles in the urinary tract. J Am Soc Nephrol Suppl. 1999;14:S430-S435.
16. Lieske JC, Toback FG, Deganello S. Face-selective adhesion of calcium oxalate dihydrate crystals to renal epithelial cells. Calcif Tissue Int. 1996;58:195-2000.
17. Khan SR. Calcium oxalate crystal interaction with renal tubular epithelium, mechanism of crystal adhesion and its impact on stone development. Urol Res. 1995;23:71-79.
18. Lieske JC, Spargo BH, Toback FG. Endocytosis of calcium oxalate crystals and proliferation of renal tubular epithelial cells in a patient with type 1 primary hyperoxaluria. J Urol. 1992;148:1517-1519.
19. Howard JE, Thomas WC. Some observations on rachitic rat cartilage of probable significance in the etiology of renal calculi. Trans Am Clin Climatol Assoc. 1958;70:94-102.
20. Ryall RL, Harnett RM, Hibberd CM, Edyvane KA, Marshall VR. Effects of chondroitin sulphate, human serum albumin and TammHorsfall mucoprotein on calcium oxalate crystallization in undiluted human urine. Urol Res. 1991;19:181-188.
21. Hoyer JR, Pietrzyk RA, Liu H, Whitson PA. Effects of microgravity on urinary osteopontin. J Am Soc Nephrol. 1999;10:389-393.
22. Ryall RL, Chauvet MC, Grover PK. Intracrystalline proteins and urolithiasis: A comparison of the protein content and ultrastructure of urinary calcium oxalate monohydrate and dihydrate crystals. BJUInt. 2005;96:654-663.
23. Bautista DS, Densteldt J, Chambers AF, Harris JF. Low molecular weight variants of osteopontin generated by serine proteases in urine of patients with kidney stones. J Cell Biochem. 1996;61:402-409.
24. Christensen B, Petersen TE, Sørensen ES. Post-translational modification and proteolytic processing of urinary osteopontin. Biochem J. 2008;411:53-61.
25. Hunter GK, Kyle CL, Goldberg HA. Modulation of crystal formation by bone phosphoproteins: structural specificity of the osteopontin-mediated inhibition of hydroxyapatite formation. Biochem J. 1994;300:723-728.
26. Hoyer JR, Asplin JR, Otvos L. Phosphorylated osteopontin peptides suppress crystallization by inhibiting the growth of calcium oxalate crystals. Kidney Int. 2001;60:77-82.
27. Rodgers AL, Mensah PD, Schwager SL, Sturrock ED. Inhibition of calcium oxalate crystallization by commercial human serum albumin and human urinary albumin isolated from two different race groups: evidence for possible molecular differences. Urol Res. 2006;34:373-380.
28. Liu J, Jiang H, Liu XY. How does bovine serum albumin prevent the formation of kidney stone? A kinetics study. J Phys Chem. 2006;110:9085-9089.
29. Hess B, Ryall RL, Kavanagh JP, et al. Methods for measuring crystallization in urolithiasis research: why, how and when? Eur Urol. 2001;40:220-230.
30. Gohel MD, Shum DK, Li MK. The dual effect of urinary macromolecules on the crystallization of calcium oxalate endogenous in urine. Urol Res. 1992;20:13-17.
31. Chow K, Dixon J, Gilpin S, Kavanagh JP, Rao PN. A stone farm: development of a method for simultaneous production of multiple calcium oxalate stones in vitro. Urol Res. 2004;32:55-60.
32. Grover PK, Ryall RL, Marshall VR. Does Tamm-Horsfall mucoprotein inhibit or promote calcium oxalate crystallization in human urine? Clin Chim Acta. 1990;190:223-238.
33. Wesson JA, Worcester EM, Wiessner JH, Mandel NS, Kleinmann JG. Control of calcium oxalate crystal structure and cell adherence by urinary macromolecules. Kidney Int. 1998;53:952-957.
34. Kramer G, Steiner GE, Prinz-Kashani M, Bursa B, Marberger M. Cell-surface matrix proteins and sialic acids in cell-crystal adhesion; the effect of crystal binding on the viability of human CAKI-1 renal epithelial cells. BJUInt. 2003;91:554-559.
35. Yasui T, Fujita K, Asai K, Kohri K. Osteopontin regulates adhesion of calcium oxalate crystals to renal epithelial cells. Int J Urol. 2002;9:100-109.
36. Lieske JC, Toback GF. Regulation of renal epithelial cell endocytosis of calcium oxalate monohydrate crystals. Am J Physiol. 1993;264:F800-F807.
37. Schepers M S J, Duim R A J, Asselman M, Romijn JC, Schroder FH, Verkoelen CF. Internalization of calcium oxalate crystals by renal tubular cells: A nephron segment-specific process? Kidney Int. 2003;64:493-500.
38. Verkoelen CF, van der Boom BG, Kok DJ, et al. Cell type-specific acquired protection from crystal adherence by renal tubule cells in culture. Kidney Int. 1999;55:1426-1433.
39. Asselman M, Verhulst A, DeBroe ME, Verkoelen CF. Calcium oxalate crystal adherence to hyaluronan-, osteopontin-, and CD44-expressing injured/regenerating tubular epithelial cells in rat kidneys. J Am Soc Nephrol. 2003;14:3155-3166.
40. Verhulst A, Asselman M, Persy VP, et al. Crystal retention capacity of cells in the human nephron: involvement of CD44 and its ligands hyaluronic acid and osteopontin in the transition of a crystal bindinginto a nonadherent epithelium. J Am Soc Nephrol. 2003;14:107-114.
41. Wiessner JH, Hasegawa AT, Hung LY, Mandel GS, Mandel NS. Mechanisms of calcium oxalate crystal attachment to injured renal collecting duct cells. Kidney Int. 2001;59:637-644.
42. Verkoelen CF, Van der Boom BG, Romijn JC. Identification of hyaluronan as a crystal-binding molecule at the surface of migrating and proliferating MDCK cells. Kidney Int. 2000;58:1045-1054.
43. Khan SR. Hyperoxaluria-induced oxidative stress and antioxidants for renal protection. Urol Res. 2005;33:349-357.
44. Scheid CR, Cao LC, Honeyman T, Jonassen JA. How elevated oxalate can promote kidney stone disease: changes at the surface and in the cytosol of renal cells that promote crystal adherence and growth. Front Biosci. 2004;9:797-808.
45. Guo C, McMartin KE. The cytotoxicity of oxalate, metabolite of ethylene glycol, is due to calcium oxalate monohydrate formation. Toxicology. 2005;208:347-355.
46. Khan SR, Atmani F, Glenton P, Hou Z, Talham DR, Khurshid M. Lipids and membranes in the organic matrix of urinary calcific crystals and stones. Calcif Tissue Int. 1996;59:357-365.
47. Khan SR, Shevock PN, Hackett RL. In vitro precipitation of calcium oxalate in the presence of whole matrix or lipid components of the urinary stones. J Urol. 1988;139:418-422.
48. Khan SR, Maslamani SA, Atmani F, et al. Membranes and their constituents as promoters of calcium oxalate crystal formation in human urine. Calcif Tissue Int. 2000;66:90-96.
49. Lieske JC, Toback FG, Deganello S. Sialic acid-containing glycoproteins on renal cells determine nucleation of calcium oxalate dihydrate crystals. Kidney Int. 2001;60:1784-1791.
50. Drach GW, Thorson S, Randolph AD. Effects of urinary organic macromolecules on crystallisation of calcium oxalate: enhancement of nucleation. J Urol. 1980;123:519-523.
51. Robertson WG, Scurr DS. Modifiers of calcium crystallization found in urine I. Studies with a continuous crystallizer using an artificial urine. J Urol. 1986;135:1322-1326.
52. Rose GA, Sulaiman S. Tamm-Horsfall mucoproteins promote calcium oxalate crystal formation in urine: quantitative studies. J Urol. 1982;127:177-179.
53. Chauvet MC, Ryall RL. Intracrystalline proteins and calcium oxalate crystal degradation in MDCK II cells. J Struct Biol. 2005;151:12-17.
54. Ryall RL, Fleming DE, Grover PK, Chauvet MC, Dean CJ, Marshall VR. The hole truth: intracrystalline proteins and calcium oxalate kidney stones. Mol Urol. 2000;4:391-402.
55. Ryall RL, Fleming DE, Doyle IR, Evans NA, Dean CJ, Marshall VR. Intracrystalline proteins and the hidden ultrastructure of calcium oxalate urinary crystals: Implications for kidney stone formation. J Struct Biol. 2001;134:5-14.
56. Sutor DJ, Wooley SE. Growth studies of calcium oxalate in the presence of various compounds and ions II. Br J Urol. 1970;42:296-301.
57. Dent CE, Sutor DJ. Presence or absence of inhibitor of calcium oxalate crystal growth in urine of normals or stone formers. Lancet. 1971; ii: 772-778.
58. Sarig S, Garti N, Azoury R, Wax Y, Perlberg S. A method for discrimination between calcium oxalate kidney stone formers and normals. J Urol. 1982;128:645-649.
59. Springmann KE, Drach GW, Gottung B, Randolph AD. Effects of human urine on aggregation of calcium oxalate crystals. J Urol. 1986;135:69-71.
60. Baumann JM, Bisaz S, Felix R, Fleisch H, Ganz U, Russell R G G. The role of inhibitors and other factors in the pathogenesis of calcium-containing renal stones. Clin Sci Mol Med. 1977;53:141-148.
61. Crassweller PO, Oreopoulos DG, Toguri A, Husdan H, Wilson DR, Rapoport A. Studies in inhibitors of calcification and levels of urine saturation with calcium oxalate in recurrent stone patients. J Urol. 1978;120:6-10.
62. Oreopoulos DG, Walker D, Akriotis DJ, et al. Excretion of inhibitors of calcification in urine, part I. Findings in control subjects and patients with renal stones. Can Med Assoc J. 1975;112:827-832.
63. Pylypchuk G, Ehrig V, Wilson DR. Differences in urine crystalloids, urine saturation with brushite and urine inhibitors of calcification between persons with and persons without recurrent kidney stone formation. Can Med Assoc J. 1979;120:658-665.
64. Ryall RL, Darroch JN, Marshall VR. The evaluation of risk factors in male stone formers attending a general hospital out-patient clinic. Br J Urol. 1984;56:116-121.
65. Ryall RL, Hibberd CM, Mazzachi BC, Marshall VR. Inhibitory activity of whole urine: a comparison of urines from stone formers and normal subjects. Clin Chim Acta. 1986;154:59-68.
66. Ryall RL, Harnett RM, Hibberd CM, Mazzachi BC, Mazzachi RD, Marshall VR. Urinary risk factors in calcium oxalate stone disease: a comparison of men and women. Br J Urol. 1987;60:480-488.
67. Asplin JR, Parks JH, Chen MS, et al. Reduced crystallization inhibition by urine from men with nephrolithiasis. Kidney Int. 1999;56:1505-1516.
68. Asplin JR, Parks JH, Nakagawa Y, Coe FL. Reduced crystallization inhibition by urine from women with nephrolithiasis. Kidney Int. 2002;61:1821-1829.
69. Bergsland KJ, Kinder JM, Asplin JR, Coe BJ, Coe FL. Influence of gender and age on calcium oxalate crystal growth inhibition by urine from relatives of stone forming patients. J Urol. 2002;167:2372-2376.
70. Ebisuno S, Umehara M, Kohjimoto Y, Ohkawa T. The effects of human urine on the adhesion of calcium oxalate crystals to MadinDarby canine kidney cells. BJU Int. 1999;84:118-122.
71. Miyake O, Kakimoto K, Tsujihata M, Yoshimura K, Takahara S, Okuyama A. Strong inhibition of crystal-cell attachment by pediatric urinary macromolecules: a close relationship with high urinary citrate secretion. Urology. 2001;58:493-497.
72. Kumar V, Pena de la Vega L, Farell G, Lieske JC. Urinary macromolecular inhibition of crystal adhesion to renal epithelial cells is impaired in male stone formers. Kidney Int. 2005;68:1784-1792.
73. Grover PK, Thurgood LA, Ryall RL. Effect of urine fractionation on the attachment of calcium oxalate crystals to renal epithelial cells: implications for studying renal calculogenesis. Am J Physiol Renal Physiol. 2007;292:F1396-F1403.
74. Kumar V, Farell G, Lieske JC. Whole urinary proteins coat calcium oxalate monohydrate crystals to greatly decrease their adhesion to renal cells. J Urol. 2003;170:221-225.
75. Wiessner JH, Hung LY, Mandel NS. Crystal attachment to injured renal collecting duct cells: influence of urine proteins and pH. Kidney Int. 2003;63:1313-1320.
76. Escobar C, Byer KJ, Khan SR. Naturally produced crystals obtained from kidney stones are less injurious to renal tubular epithelial cells than synthetic crystals. BJU Int. 2007;100:891-897.
77. Lieske JC, Leonard R, Toback FG. Adhesion of calcium oxalate monohydrate crystals to renal epithelial cells is inhibited by specific anions. Am J Physiol. 1995;268:F604-F612.
78. Lieske JC, Norris R, Toback FG. Adhesion of hydroxyapatite crystals to anionic sites on the surface of renal epithelial cells. Am J Physiol. 1997;273:F224-F233.
79. Lieske JC, Farell G, Deganello S. The effect of ions at the surface of calcium oxalate monohydrate crystals on cell-crystal interactions. Urol Res. 2004;32:117-123.
80. Rabinovich YI, Daosukho S, Byer KJ, El-Shall HE, Khan SR. Direct AFM measurements of adhesion forces between calcium oxalate monohydrate and kidney epithelial cells in the presence of Ca2+ and Mg2+ ions. J Colloid Interface Sci. 2008;325:594-601.
81. Tsujihata M, Yoshimura K, Tsujikawa K, Tei N, Okuyama A. Fibronectin inhibits endocytosis of calcium oxalate crystals by renal tubular cells. Int J Urol. 2006;13:743-746.
82. Tsujikawa K, Tsujihata M, Tei N, Yoshimura K, Nonomura N, Okuyama A. Elucidation of the mechanism of crystal-cell interaction using fibronectin-overexpressing Madin-Darby canine kidney cells. Urol Int. 2007;79:157-163.
83. Ebisuno S, Nishihata M, Inagaki T, Umehara M, Kohjimoto Y. Bikunin prevents adhesion of calcium oxalate crystals to renal tubular cells in human urine. J Am Soc Nephrol Suppl. 1999;14:S436-440.
84. Tsujihata M, Momohara C, Yoshioka I, Tsujimura A, Nonomura N, Okuyama A. Atorvastatin inhibits renal crystal retention in a rat stone forming model. J Urol. 2008;180:2212-2217.
85. Thongboonkerd V, Semangoen T, Sinchaikul S, Chen ST. Proteomic analysis of calcium oxalate monohydrate crystalinduced toxicity in distal renal tubular cells. J Proteome Res. 2008;7:4689-4700.
86. Semangoen T, Sinchaikul S, Chen ST, Thongboonkerd V. Altered proteins in MDCK renal tubular cells in response to calcium oxalate dihydrate crystal adhesion: a proteomics approach. J Proteome Res. 2008;7:2889-2896.
87. Yamate T, Kohri K, Umekawa T, et al. The effect of osteopontin on the adhesion of calcium oxalate crystals to Madin-Darby Canine Kidney cells. Eur Urol. 1996;30:388-393.
88. Yamate T, Kohri K, Umekawa T, Iguchi M, Kurita T. Osteopontin antisense oligonucleotide inhibits adhesion of calcium oxalate crystals in Madin-Darby canine kidney cells. J Urol. 1998;160:1506-1512.
89. Sorokina EA, Wesson JA, Kleinman JG. An acidic peptide sequence of nucleolin-related protein can mediate the attachment of calcium oxalate to renal tubule cells. J Am Soc Nephrol. 2004;15:2057-2065.
90. Koul HK, Koul S. b-tubulin is the major cell membrane COMcrystal binding protein in renal epithelial cells. in: Gohel MDI, Au DWT, eds. Kidney Stones: Inside and Out. Hong Kong: The Hong Kong Polytechnic University; 2004:123-126.
91. Farell G, Huang E, Kim SY, Horstkorte R, Lieske JC. Modulation of proliferating renal epithelial cell affinity for calcium oxalate monohydrate crystals. J Am Soc Nephrol. 2004;15:3052-3062.
92. Kramer G, Steiner GE, Neumayer C, et al. Over-expression of anti-CD75 reactive proteins on distal and collecting renal tubular epithelial cells in calcium oxalate stone-forming kidneys in Egypt. BJU Int. 2004;93:822-826.
93. Sayer JA, Carr G, Pearce SH, Goodship TH, Simmons NL. Disordered calcium crystal handling in antisense CLC-5-treated collecting duct cells. Biochem Biophys Res Commun. 2003;300:305-10.
94. Sayer JA, Carr G, Simmons NL. Calcium phosphate and calcium oxalate crystal handling is dependent upon CLC-5 expression in mouse collecting duct cells. Biochim Biophys Acta. 2004;1689:83-90.
95. Verkoelen CF, Romijn JC, deBruijn WC, Boeve ER, Cao LC, Schroder FH. Association of calcium oxalate monohydrate crystals with MDCK cells. Kidney Int. 1995;48:129-138.
96. deWater R, Leenen P J M, Nordermeer C, et al. Cytokine production induced by binding and processing of calcium oxalate crystals in cultured macrophages. Am J Kidney Dis. 2001;38:331-338.
97. deWater R, Noordermeer C, van der Kwast TH, et al. Calcium oxalate nephrolithiasis: effect of renal crystal deposition on the cellular composition of the renal interstitium. Am J Kidney Dis. 1999;33:761-771.
98. Lieske JC, Deganello S. Nucleation, adhesion and internalization of calcium-containing urinary crystals by renal cells. J Am Soc Nephrol. 1999;10:S422-S429.
99. Lieske JC, Deganello S, Toback FG. Cell-crystal interactions and kidney stone formation. Nephron. 1999;81(Suppl 1):8-17.
100. Fleming DE, van Riessen A, Chauvet MC, et al. Intracrystalline proteins and urolithiasis: A synchrotron X-ray diffraction study of calcium oxalate monohydrate. J Bone Miner Res. 2003;18:1282-1291.
101. Ryall RL, Grover PK, Thurgood LA, Chauvet MC, Fleming DE, van Bronswijk W. The importance of a clean face: The effect of different washing procedures on the association of Tamm-Horsfall glycoprotein and other urinary proteins with calcium oxalate crystals. Urol Res. 2007;35:1-14.
102. Stapleton A M F, Ryall RL. Blood coagulation proteins and urolithiasis are linked: crystal matrix protein is the F1 activation peptide of human prothrombin. Br J Urol. 1995;75:712-719.
103. Stapleton A M F, Simpson RJ, Ryall RL. Crystal matrix protein is related to human prothrombin. Biochem Biophys Res Commun. 1993;195:1199-1203.
104. Cook AF, Grover PK, Ryall RL. Face-specific binding of prothrombin fragment 1 and human serum albumin to inorganic and urinary calcium oxalate monohydrate crystals. BJU Int. 2008;103(6):826-835.
105. Ryall RL. Macromolecules and urolithiasis: parallels and paradoxes. Nephron Physiol. 2004;98:37-42.
106. Grover PK, Thurgood LA, Fleming DE, van Bronswijk W, Wang T, Ryall RL. Intracrystalline urinary proteins facilitate degradation and dissolution of calcium oxalate crystals in cultured renal cells. Am J Physiol Renal Physiol. 2007;278:F130-F137.
107. Fleisch H, Bisaz S. Isolation from urine of pyrophosphate, a calcification inhibitor. Am J Physiol. 1962;203:671-675.
108. March JG, Simonet BM, Grases F. Determination of pyrophosphate in renal calculi and urine by means of an enzymatic method. Clin Chim Acta. 2001;314:187-194.
109. Doremus RH, Teich S, Silvis PX. Crystallization of calcium oxalate from synthetic urine. Invest Urol. 1978;15:469-472.
110. Sutor DJ. Growth studies of calcium oxalate in the presence of various ions and compounds. Br J Urol. 1969;41:171-178.
111. Welshman SG, McGeown MG. A quantitative investigation of the effects on the growth of calcium oxalate crystals of potential inhibitors. Br J Urol. 1972;44:677-680.
112. Ryall RL, Harnett RM, Marshall VR. The effect of urine, pyrophosphate, citrate, magnesium and glycosaminoglycans on the growth and aggregation of calcium oxalate crystals in vitro. Clin Chim Acta. 1981;112:349-356.
113. Robertson WG, Peacock M, Nordin B E C. Inhibitors of the growth and aggregation of calcium oxalate crystals in vitro. Clin Chim Acta. 1973;43:31-37.
114. Ryall RL, Hibberd CM, Marshall VR. A method for studying inhibitory activity in whole urine. Urol Res. 1985;13:285-289.
115. Hallson PC, Rose GA, Sulaiman S. Pyrophosphate does not influence calcium oxalate or calcium phosphate crystal formation in concentrated whole human urine. Urol Res. 1983;11:151-154.
116. Fleisch H, Bisaz S. Mechanism of calcification: inhibitory role of pyrophosphate. Nature. 1962;195:911.
117. Roberts NB, Dutton J, Helliwell T, Rothwell PJ, Kavanagh JP. Pyrophosphate in synovial fluid and urine and its relationship to urinary risk factors for stone disease. Ann Clin Biochem. 1992;29:529-534.
118. Schwille PO, Rumenapf G, Wolfel G, Kohler R. Urinary pyrophosphate in patients with recurrent calcium urolithiasis and in healthy controls: a re-evaluation. J Urol. 1988;140:239-245.
119. Sharma S, Vaidyanathan S, Thind SK, Nath R. Urinary excretion of inorganic pyrophosphate by normal subjects and patients with renal calculi in north-western India and the effect of diclofenac sodium upon urinary excretion of pyrophosphate in stone formers. Urol Int. 1992;48:404-408.
120. Wikstrom B, Danielson BG, Ljunghall S, McGuire M, Russell R G G. Urinary pyrophosphate excretion in renal stone formers with normal and impaired renal function. World J Urol. 1983;1:150-154.
121. O'Brien MM, Uhlemann I, McIntosh HW. Urinary pyrophosphate in normal subjects and in stone formers. Can Med Assoc J. 1967;96:100-103.
122. Robertson WG, Peacock M, Heyburn PJ, Marshall DH, Clark PB. Risk factors in calcium stone disease of the urinary tract. Br J Urol. 1978;50:449-454.
123. Russell R G G, Hodgkinson A. The urinary excretion of inorganic pyrophosphate by normal subjects and patients with renal calculus. Clin Sci. 1966;31:51-62.
124. Schlieper G, Westenfeld R, Brandenberg V, Ketteler M. Inhibitors of calcification in blood and urine. Semin Dial. 2007;20:113-121.
125. Moochhala SH, Sayer JA, Carr G, Simmons NL. Renal calcium stones: insights from the control of bone mineralization. Exp Physiol. 2007;93(1):43-49.
126. Costa-Bauza A, Isern B, Perello J, Sanchis P, Grases F. Factors affecting the regrowth of renal stones in vitro: a contribution to the understanding of renal stone development. Scand J Urol Nephrol. 2005;39:194-199.
127. Cramer W. Experimental production of kidney lesions by diet. Lancet. 1932; ii: 174-175.
128. Li MK, Blacklock NJ, Garside J. Effects of magnesium on calcium oxalate crystallization. J Urol. 1985;133:123-125.
129. Azoury R, Garside J, Robertson WG. Calcium oxalate precipitation in a flow system: an attempt to simulate the early stages of stone formation in the renal tubules. J Urol. 1986;136:150-153.
130. Bertoni E, Bigi A, Cojazzi G, Gandolfi M, Panzavolta S, Roveri N. Nanocrystals of magnesium and fluoride substituted hydroxyapatite. J Inorganic Biochem. 1998;72:29-35.
131. Meyer JL, Smith LH. Growth of calcium oxalate crystals. II. Inhibition by natural crystal growth inhibitors. Invest Urol. 1975;13:36-39.
132. Ryall RL, Grover PK, Harnett RM, Hibberd CM, Marshall VR. Small molecular weight inhibitors. In: Walker VR, Sutton RAL, Cameron EC, Pak CYC, Robertson WG, eds. Urolithiasis. New York: Plenum; 1989:91-96.
133. Hallson PC, Rose GA, Sulaiman S. Magnesium reduces calcium oxalate crystal formation in human whole urine. Clin Sci. 1982;62:17-19.
134. Atakan IH, Kaplan M, Seren G, Aktoz T, Gul H, Inci O. Serum, urinary and stone zinc, iron, magnesium and copper levels in idiopathic calcium oxalate stone patients. Int Urol Nephrol. 2007;39:351-356.
135. Ogawa Y, Yonou H, Hokama S, Oda M, Morozumi M, Sugaya K. Urinary saturation and risk factors for calcium oxalate stone disease based on spot and 24-hour urine specimens. Front Biosci. 2003;8:a167-76.
136. Trinchieri A, Mandressi A, Luongo P, Rovera F, Longo G. Urinary excretion of citrate, glycosaminoglycans, magnesium and zinc in relation to age and sex in normal subjects and in patients who form calcium stones. Scand J Urol Nephrol. 1992;26:379-386.
137. Bach D, Hesse A, Strenge A, Vahlensieck W. Magnesium excretion in urine on condition of individual standard diet in healthy controls and calcium oxalate stone formers. in: Smith LH, Robertson WG, Finlayson B, eds. Urolithiasis: Clinical and Basic Research. New York: Plenum; 1981:45-49.
138. Johansson G, Backman U, Danielson BG, Fellstrom B, Ljunghall S. Biochemical and clinical effects of the prophylactic treatment of renal calcium stones with magnesium hydroxide. J Urol. 1980;124:770-774.
139. Resnick MI, Munday D, Boyce WH. Magnesium excretion and calcium oxalate urolithiasis. Urology. 1982;20:385-389.
140. Robertson WG, Peacock M, Nordin B E C. Activity products in stone-forming and non-stone-forming urines. Clin Sci. 1968;34:579-594.
141. Stejskal D, Karpisek M, Vrtal R, et al. Urine fetuin-A values in relation to the presence of urolithiasis. BJU Int. 2008;101:1151-1154.
142. Su CJ, Shevock PN, Khan SR, Hackett RL. Effect of magnesium on calcium oxalate urolithiasis. J Urol. 1991;145:1092-1095.
143. Khan SR, Shevock PN, Hackett RL. Magnesium oxide administration and prevention of calcium oxalate nephrolithiasis. J Urol. 1993;149:412-416.
144. Ogawa Y, Yamaguchi K, Morozumi M. Effects of magnesium salts in preventing experimental urolithiasis in rats. J Urol. 1990;144:385-389.
145. Ryall RL, Marshall VR. The value of the 24hr urine analysis in the assessment of stone formers attending a general hospital outpatient clinic. Br J Urol. 1983;55:1-5.
146. Massey L. Magnesium therapy for nephrolithiasis. Magnes Res. 2005;18:123-126.
147. Hallson PC, Rose GA, Sulaiman S. Raising urinary citrate lowers calcium oxalate and calcium phosphate crystal formation in whole urine. Urol Int. 1983;38:179-181.
148. Qiu SR, Wierzbicki A, Orme CA, et al. Molecular modulation of calcium oxalate crystallization by osteopontin and citrate. PNAS. 2004;101:1811-1815.
149. Qiu SR, Wierzbicki A, Salter A, et al. Modulation of calcium oxalate monohydrate crystallization by citrate through selective binding to atomic steps. J Am Chem Soc. 2005;127:9036-9044.
150. Kok DJ, Papapoulos SE, Bijvoet O L M. Excessive crystal agglomeration with low citrate excretion in recurrent stone formers. Lancet. 1986; i: 1056-1058.
151. Shorr E, Almy TP, Sloan MH, Taussky H, Toscani V. The relation between the urinary excretion of citric acid and calcium: its implications for urinary calcium stone formation. Science. 1942;96:587-588.
152. Curhan GC, Willett WC, Speizer FE, Stampfer MJ. Twenty-fourhour urine chemistries and the risk of kidney stones among women and men. Kidney Int. 2001;59:2290-2298.
153. Mithani S, Zaidi Z. Comparison of 24 hours urinary citrate levels in urolithiasis patients and healthy controls. J Pak Med Assoc. 2005;55:371-373.
154. Shah O, Assimos DG, Holmes RP. Genetic and dietary factors in urinary citrate excretion. J Endourol. 2005;19:177-181.
155. Cupisti A, Morelli E, Lupetti S, Meola M, Barsotti G. Low urine citrate excretion as a main risk factor for recurrent calcium oxalate nephrolithiasis in males. Nephron. 1992;61:73-76.
156. Domrongkitchaiporn S, Stitchantrakul W, Kochakarn W. Causes of hypocitraturia in recurrent stone formers: focusing on urinary potassium excretion. Am J Kidney Dis. 2006;48:546-554.
157. Pak C Y C. Citrate and renal calculi: an update. Min Electrolyte Metab. 1994;20:371-377.
158. Rudman D, Kutner MH, Redd SC, Waters WC, Gerron GG, Bleier J. Hypocitraturia in calcium nephrolithiasis. J Clin Endocrinol Metab. 1982;55:1050-1057.
159. Goldberg H, Grass L, Vogl R, Rapoport A, Oreopoulos DG. Urine citrate and renal stone disease. CMAJ. 1989;141:217-221.
160. Curhan GC, Taylor EN. 24-h uric acid excretion and the risk of kidney stones. Kidney Int. 2008;73:489-496.
161. Ebisuno S, Morimoto S, Yoshida T, Fukatani T, Yasukawa S, Ohkawa T. Effect of dietary calcium and magnesium on experimental tubular deposition of calcium oxalate crystals induced by ethylene glycol administration and its prevention with phytin and citrate. Urol Int. 1987;42:330-337.
162. Ogawa Y, Tanaka T, Yamaguchi K, Morozumi M, Kitagawa R. Effects of sodium citrate, potassium citrate, and citric acid in preventing experimental calc oxalate urolithiasis in rats. Hinyokika Kiyo. 1987;33:1772-1777.
163. Selvam R, Bijikurien T. Effect of citrate on free radical induced changes in experimental urolithiasis. Indian J Exp Biol. 1992;30:705-710.
164. Yasui T, Sato M, Fujita K, Tozawa K, Nomura S, Kohri K. Effects of citrate on renal stone formation and osteopontin expression in a rat urolithiasis model. Urol Res. 2001;29:50-56.
165. Zhou JR, Erdman JW. Phytic acid in health and disease. Crit Rev Food Sci Nutr. 1995;35:495-508.
166. Modlin M. Urinary phosphorylated inositols and renal stone. Lancet. 1980;2:1113-1114.
167. Ohkawa T, Ebisuno S, Kitagawa M, Morimoto S, Miyazaki Y, Yasukawa S. Rice bran treatment for patients with hypercalciuric stones: experimental and clinical studies. J Urol. 1984;132:1140-1145.
168. Shah PJ, Green NA, Williams G. Unprocessed bran and its effect on urinary calcium excretion in idiopathic hypercalciuria. Br Med J. 1980;281:426.
169. Grases F, Garcia-Gonzalez R, Torres JJ, Llobera A. Effects of phytic acid on renal stone formation in rats. Scan J Urol Nephrol. 1998;32:261-265.
170. Grases F, Costa-Bauza A. Phytate (IP6) is a powerful agent for preventing calcifications in biological fluids: usefulness in renal lithiasis treatment. Anticancer Res. 1999;19:3717-3722.
171. Grases F, Simonet BM, March JG, Prieto RM. Inositol hexakisphosphate in urine: the relationship between oral intake and urinary excretion. BJUInt. 2000;85:138-142.
172. Grases F, March JG, Prieto RM, et al. Urinary phytate in calcium oxalate stone formers and healthy people - dietary effects on phytate excretion. Scan J Urol Nephrol. 2000;34:162-164.
173. Grases F, Perello J, Simonet BM, Prieto RM, Garcia-Raja A. Study of potassium phytate effects on decreasing urinary calcium in rats. Urol Int. 2004;72:237-243.
174. Wu N, Thon WF, Krah H, Schlick R, Jonas U. Effects of magnesium citrate and phytin on reducing urinary calcium excretion in rats. World J Urol. 1994;12:323-328.
175. Grases F, Isern B, Sanchis P, Perello J, Torres JJ, Costa-Bauza A. Phytate acts as an inhibitor in formation of renal calculi. Front Biosci. 2007;12:2580-2587.
176. Costa-Bauza A, Perello J, Isern B, Sanchis P, Grases F. Factors affecting calcium oxalate dihydrate fragmented regrowth. BMC Urol. 2006;5:6-16.
177. Raboy V. Progress in breeding low phytate crops. J Nutr. 2002;132:503S-505S.
178. Thomas E, von Unruh GE, Hesse A. Influence of a lowand a high-oxalate vegetarian diet on intestinal absorption and urinary excretion. Eur J Clin Nutr. 2008;62:1090-1097.
179. Boyce WH. Organic matrix of human urinary concretions. Am J Med. 1968;45:673-683.
180. Khan SR, Kok DJ. Modulators of urinary stone formation. Front Biosci. 2004;9:1450-1482.
181. Nagatsuka Y, Sato K, Ototani N, Yosizawa Z. A method of screening test for excretion pattern of urinary glycosaminoglycans and its application to normal human urine. Tohoku J Exp Med. 1980;132:159-171.
182. Gohel MD, Shum DK, Tam PC. Electrophoretic separation and characterization of urinary glycosaminoglycans and their roles in urolithiasis. Carbohydr Res. 2007;342:79-86.
183. Goldberg JM, Cotlier E. Specific isolation and analysis of mucopolysaccharides (glycosaminoglycans) from human urine. Clin Chim Acta. 1972;41:19-27.
184. Heintz B, Stocker G, Mrowka C, et al. Decreased glomerular basement membrane heparan sulphate proteoglycan in essential hypertension. Hypertension. 1995;25:399-407.
185. Manley G, Severn M, Hawksworth J. Excretion patterns of glycosaminoglycans and glycoproteins in normal human urine. J Clin Pathol. 1968;21:339-345.
186. Shum DK, Gohel MD, Tam PC. Hyaluronans: crystallization-promoting activity and HPLC analysis of urinary excretion. J Am Soc Nephrol Suppl. 1999;14:S397-S403.
187. Nishio S, Abe Y, Wakatsuki A, et al. Matrix glycosaminoglycan in urinary stones. J Urol. 1985;143:503-505.
188. Roberts SD, Resnick MI. Glycosaminoglycans content of stone matrix. J Urol. 1986;135:1078-1083.
189. Fellstrom B, Danielson BG, Ljunghall S, Wikstrom B. Crystal inhibition: the effects of polyanions on calcium oxalate crystal growth. Clin Chim Acta. 1986;158:229-235.
190. Sheng X, Jung T, Wesson JA, Ward MD. Adhesion at calcium oxalate crystal surfaces and the effect of urinary constituents. PNAS. 2005;102:267-272.
191. Kohri K, Garside J, Blacklock NJ. The effect of glycosaminoglycans on the crystallization of calcium oxalate. Br J Urol. 1989;63:584-590.
192. Pak C Y C, Holt K, Zerwekh JE. Attenuation by monosodium urate of the inhibitory effect of glycosaminoglycans on calcium oxalate nucleation. Invest Urol. 1979;17:138-140.
193. Scurr DS, Robertson WG. Modifiers of calcium oxalate crystallization found in urine. II. Studies on their mode of action in an artificial urine. J Urol. 1986;136:128-131.
194. Michelacci YM, Boim MA, Bergamaschi CT, Rovigatti RM, Schor N. Possible role for chondroitin sulfate in urolithiasis: in vivo studies in an experimental model. Clin Chim Acta. 1992;208:1-8.
195. Osswald H, Weinheimer G, Schutt I-D, Ernst W. Effective prevention of calcium-oxalate crystal formation in vitro and in vivo by pentosan polysulfate. in: Walker VR, Sutton RAL, Cameron ECB, Pak CYC, Robertson WG, eds. Urolithiasis. New York and London: Plenum; 1989:141-144.
196. Suzuki K, Ryall RL. The effect of heparan sulphate on the crystallization of calcium oxalate in undiluted, ultrafiltered human urine. Br J Urol. 1996;78:15-21.
197. Shum DK, Gohel MD. Separate effects of urinary chondroitin sulphate and heparan sulphate on the crystallization of urinary calcium oxalate: differences between stone formers and normal control subjects. Clin Sci. 1993;85:33-39.
198. Takazono I. Role of heparan sulphate proteoglycans (syndecan 1) on the renal epithelial cells during calcium oxalate monohydrate crystal attachment. Kurume Med J. 2002;49:201-210.
199. Iida S, Inoue M, Yoshii S, et al. Molecular detection of heparan sulphate proteoglycan mRNA in rat kidney during calcium oxalate nephrolithiasis. J Am Soc Nephrol. 1999;14:S412-S416.
200. Eguchi Y, Inoue M, Iida S, Matsuoka K, Noda S. Heparan sulfate (HS)/heparan sulfate proteoglycan (HSPG) and bikunin are upregulated during calcium oxalate nephrolithiasis in rat kidney. Kurume Med. 2002;49:99-107.
201. Verkoelen CF. Crystal retention in renal stone disease: a crucial role for the glycosaminoglycan hyaluronan. J Am Soc Nephrol. 2006;17:1673-1687.
202. Borges FT, Michelacci YM, Aguiar JA, Dalboni MA, Garofalo AS, Schor N. Characterization of glycosaminoglycans in tubular epithelial cells: calcium oxalate and oxalate ions effects. Kidney Int. 2005;68:1630-1642.
203. Cao LC, Boeve ER, Schroder FH, Robertson WG, Ketelaars G A M, Bruijn D. The effect of two new semi-synthetic glycosaminoglycans (G871, G872) on the zeta potential of calcium oxalate crystals and on growth and agglomeration. J Urol. 1992;147:1643-1646.
204. Grases F, Gil JJ, Conte A. Glycosaminoglycans inhibition of calcium oxalate crystalline growth and promotion of crystal aggregation. Coll Surf. 1989;36:29-38.
205. Martin X, Werness PG, Bergert JH, Smith LH. Pentosan polysulfate as an inhibitor of calcium oxalate crystal growth. J Urol. 1984;132:786-788.
206. Norman RW, Scurr DS, Robertson WG, Peacock M. Inhibition of calcium oxalate crystallisation by pentosan polysulphate in control subjects and stone formers. Br J Urol. 1984;56:594-598.
207. Suzuki K, Miyazawa K, Tsugawa R. Inhibitory effect of sodium pentosan polysulfate on the formation, growth and aggregation of calcium oxalate in vitro. Jpn J Urol. 1989;80:526-531.
208. Miyazawa K, Suzuki K, Tsugawa R. The quantitative study of inhibitory effect of pentosan polysulfate and chlorophyllin on the experimental calcium oxalate stone. Jpn J Urol. 1989;80:861-869.
209. Jones M, Monga M. Is there a role for pentosan polysulfate in the prevention of calcium oxalate stones? JEndourol. 2003;17:855-858.
210. Baggio B, Gambaro G, Cicerello E, et al. Urinary excretion of glycosaminoglycans in urological disease. Clin Biochem. 1987;20:449-450.
211. Michelacci YM, Glashan RQ, Schor N. Urinary excretion of glycosaminoglycans in normal and stone forming subjects. Urol Int. 1989;44:218-221.
212. Nesse A, Garbossa G, Romero MC, Bogardo CE, Zanchetta JR. Glycosaminoglycans in urolithiasis. Nephron. 1992;62:36-39.
213. Nikkila MT. Urinary glycosaminoglycan excretion in normal and stone-forming subjects: significant disturbance in recurrent stone formers. Urol Int. 1989;44:157-159.
214. Hwang T I S, Preminger GM, Poindexter J, Pak C Y C. Urinary glycosaminoglycans in normal subjects and patients with stones. J Urol. 1988;139:995-997.
215. Akinci N, Esen T, Kocak T, Ozsoy C, Tellaloglu S. The role of inhibitor deficiency in urolithiasis. I. Rationale of urinary magnesium, citrate, pyrophosphate and glycosaminoglycan determinations. Eur Urol. 1992;19:240-243.
216. Caudarella R, Stefani F, Rizzoli E, Malavolta N, D'Antuono G. Preliminary results of glycosaminoglycans excretion in normal and stone forming subjects: Relationship with uric acid excretion. J Urol. 1983;129:665-667.
217. Hesse A, Wuzel H, Vahlensieck W. The excretion of glycosaminoglycans in the urine of calcium-oxalate-stone patients and healthy persons. Urol Int. 1986;41:81-87.
218. Ryall RL, Marshall VR. The relationship between urinary inhibitory activity and endogenous concentrations of glycosaminoglycans and uric acid: comparison of urines from stone formers and normal subjects. Clin Chim Acta. 1984;141:197-204.
219. Samuell CT. A study of glycosaminoglycan excretion in normal and stone-forming subjects using a modified cetylpyridinium chloride technique. Clin Chim Acta. 1981;117:63-73.
220. Harangi F, Gyorke Z, Melegh B. Urinary glycosaminoglycan excretion in healthy and stone forming children. Pediatr Nephrol. 1996;10:555-558.
221. Lama G, Carbone MG, Marrone N, Russo P, Spagnolo G. Promoters and inhibitors of calcium urolithiasis in children. Child Nephrol Urol. 1990;10:81-84.
222. Nakagawa Y, Margolis HC, Yokoyama S, Kezdy FJ, Kaiser ET, Coe FL. Purification and characterization of a calcium oxalate monohydrate crystal growth inhibitor from human kidney tissue culture medium. J Biol Chem. 1981;256:3936-3944.
223. Worcester EM, Nakagawa Y, Wabner CL, Kumar S, Fl C. Crystal adsorption and growth slowing by nephrocalcin, albumin, and Tamm-Horsfall protein. Am J Physiol Renal Physiol. 1988;255:F1197-F1205.
224. Tang Y, Grover PK, Moritz RL, Simpson RJ, Ryall RL. Is nephrocalcin related to the urinary derivative (bikunin) of inter-a-trypsin inhibitor? Br J Urol. 1995;76:425-30.
225. Canales BK, Anderson L, Higgins L, et al. Comprehensive proteomic analysis of human calcium oxalate monohydrate kidney stone matrix. aJ Endourol. 2008;22:1161-1167.
226. Kaneko K, Yamanobe T, Nakagomi K, Mawatari K, Onoda M, Fujimori S. Detection of protein Z in a renal calculus composed of calcium oxalate monohydrate with the use of liquid chromatography-mass spectrometry/mass spectrometry following two-dimensional polyacrylamide gel electrophoresis separation. Anal Biochem. 2004;324:191-196.
227. Merchant M, Cummins T, Wilkey D, et al. Proteomic analysis of renal calculi indicates an important role for inflammatory processes in calcium stone formation. Am J Physiol Renal Physiol. 2008;295:F1254-258.
228. Mushtaq S, Siddiqui AA, Naqvi ZA, et al. Identification of myeloperoxidase, alpha-defensin and calgranulin in calcium oxalate renal stones. Clin Chim Acta. 2007;284:41-47.
229. Gonzalez-Buitrago JM, Ferreira L, Lorenzo I. Urinary proteomics. Clin Chim Acta. 2007;375:49-56.
230. Chen WC, Lai CC, Tsai Y, Lin WY, Tsai FJ. Mass spectroscopic characteristics of low molecular weight proteins extracted from calcium oxalate stones: preliminary study. J Clin Lab Anal. 2008;22:77-85.
231. Miyazawa K, Domiki C, Moriyama M, Suzuki K. cDNA macroarray analysis of genes in renal epithelial cells exposed to calcium oxalate crystals. in: Gohel MDI, Au DWT, eds. Kidney Stones: Inside and Out. Hong Kong: The Hong Kong Polytechnic University; 2004:130-131.
232. Morse RM, Resnick MI. A new approach to the study of urinary macromolecules as a participant in calcium oxalate crystallization. J Urol. 1988;139:869-873.
233. Doyle IR, Ryall RL, Marshall VR. Inclusion of proteins into calcium oxalate crystals precipitated from human urine: A highly selective phenomenon. Clin Chem. 1991;37:1589-1594.
234. Hess B. The role of Tamm-Horsfall glycoprotein and nephrocalcin in calcium oxalate monohydrate crystallization processes. Scan Microsc. 1991;5:689-696.
235. Hess B. Tamm-Horsfall glycoprotein - Inhibitor or promoter of calcium oxalate monohydrate crystallization processes? Urol Res. 1992;20:83-86.
236. Atmani F, Khan SR. Quantification of proteins extracted from calcium oxalate and calcium phosphate crystals induced in vitro in the urine of healthy controls and stone-forming patients. Urol Int. 2002;68:54-59.
237. Atmani F, Glenton PA, Khan SR. Identification of proteins extracted from calcium oxalate and calcium phosphate crystals in the urine of healthy and stone forming subjects. Urol Res. 1998;26:201-207.
238. Maslamani S, Glenton PA, Khan SR. Changes in urine macromolecular composition during processing. J Urol. 2000;164:230-236.
239. Walton RC, Kavanagh JP, Heywood BR, Rao PN. The association of different urinary proteins with calcium oxalate hydromorphs. Evidence for non-specific interactions. Biochim Biophys Acta. 2005;1723:175-183.
240. Deganello S. The interaction between nephrocalcin and TammHorsfall proteins with calcium oxalate dihydrate. Scan Microsc. 1993;7:1111-1118.
241. Miyake O, Yoshioka T, Yoshimura K, et al. Expression of TammHorsfall protein in stone-forming rat models. Br J Urol. 1998;81:14-19.
242. Mo L, Huang HY, Zhu XH, Shapiro E, Hasty DL, Wu XR. Tamm-Horsfall protein is a critical renal defense factor protecting against calcium oxalate crystal formation. Kidney Int. 2004;66:1159-1166.
243. Grover PK, Moritz RL, Simpson RJ, Ryall RL. Inhibition of calcium oxalate crystal growth and aggregation in vitro. A comparison of four human proteins. Eur J Biochem. 1998;253:637-644.
244. Kitamura T, Pak C Y C. Tamm and Horsfall glycoprotein does not promote spontaneous precipitation and crystal growth of calcium oxalate in vitro. J Urol. 1982;127:1024-1026. Eur J Biochem
245. Rose GA, Sulaiman S. Tamm-Horsfall mucoprotein promotes calcium phosphate crystal formation in urine: quantitative studies. Urol Res. 1984;12:217-221.
246. Grover PK, Ryall RL, Marshall VR. Tamm-Horsfall mucoprotein reduces promotion of calcium oxalate crystal aggregation induced by urate in human urine in vitro. Clin Sci. 1994;87:137-144.
247. Serafini-Cessi F, Monti A, Cavallone D. N-Glycans carried by Tamm-Horsfall glycoprotein have a crucial role in the defense against urinary tract disease. Glycoconj J. 2005;22:383-394.
248. Hsieh N, Shih CH, Chen HY, Wu MC, Chen WC, Li CW. Effects of Tamm-Horsfall protein on the protection of MDCK cells from oxalate induced free radical injury. Urol Res. 2003;31:10-16.
249. Schnierle P. A simple diagnostic test for the differentiation of Tamm-Horsfall glycoproteins from healthy probands and those from recurrent calcium oxalate renal stone formers. Experientia. 1995;51:1068-1072.
250. Knorle R, Schnierle P, Koch A, et al. Tamm-Horsfall glycoprotein: role in inhibition and promotion of renal calcium oxalate stone formation studied with Fourier transform infrared spectroscopy. Clin Chem. 1994;40:1739-1743.
251. Hallson PC, Choong SK, Kasidas GP, Samuell CT. Effects of Tamm-Horsfall protein with normal and reduced sialic acid content upon the crystallization of calcium phosphate and calcium oxalate in human urine. Br J Urol. 1997;80:533-538.
252. Jaggi M, Nakagawa Y, Zipperle L, Hess B. Tamm-Horsfall protein in recurrent calcium kidney stone formers with positive family history: abnormalities in urinary excretion, molecular structure and function. Urol Res. 2007;35:55-62.
253. Grover PK, Resnick MI. Evidence for the presence of abnormal proteins in the urine of recurrent stone formers. J Urol. 1995;153:1716-1721.
254. Trewick AL, Rumsby G. Isoelectric focusing of native urinary uromodulin (Tamm-Horsfall protein) shows no physicochemical differences between stone formers and non-stone formers. Urol Res. 2000;27:250-254.
255. Gokhale JA, Glenton PA, Khan SR. Characterization of TammHorsfall protein in a rat nephrolithiasis model. J Urol. 2001;166:L1492-1497.
256. Marengo SR, Chen DH, Kaung HL, Resnick MI, Yang L. Decreased renal expression of the putative calcium oxalate inhibitor Tamm-Horsfall protein in the ethylene glycol rat model of calcium oxalate urolithiasis. J Urol. 2002;167:2192-2197.
257. Gokhale JA, McKee MD, Khan SR. Localization of TammHorsfall protein and osteopontin in a rat nephrolithiasis model. Nephron. 1996;73:456-461.
258. Gokhale JA, McKee MD, Khan SR. Immunocytochemical localization of Tamm-Horsfall protein in the kidneys of normal and nephrolithic rats. Urol Res. 1996;24:201-209.
259. Bichler KH, Kirchner C, Ideler V. Uromucoid excretion of normal individuals and stone formers. Br J Urol. 1976;47:733-738.
260. Grant A M S, Baker L R I, Neuberger A. Urinary Tamm-Horsfall glycoprotein in certain kidney disease and its content in renal and bladder calculi. Clin Sci. 1973;44:377-384.
261. Pourmand G, Nasseh H, Sarrafnejad A, et al. Comparison of urinary proteins in calcium stone formers and healthy individuals: a case-control study. Urol Int. 2006;76:163-168.
262. Glauser A, Hochreiter W, Jaeger P, Hess B. Determinants of urinary excretion of Tamm-Horsfall protein in non-selected kidney stone formers and healthy subjects. Nephrol Dial Transplant. 2000;15:1580-1587.
263. Lau WH, Leong WS, Ismail Z, Gam LH. Qualification and application of an ELISA for the determination of Tamm-Horsfall protein (THP) in human urine and its use for screening of kidney stone disease. Int J Biol Sci. 2008;4:215-222.
264. Romero MC, Nocera S, Nesse AB. Decreased Tamm-Horsfall protein in lithiasic patients. Clin Biochem. 1997;30:63-67.
265. Bichler K, Mittermuller B, Strohmaier WL, Feil G, Eipper E. Excretion of Tamm-Horsfall protein in patients with uric acid stones. Urol Int. 1999;62:87-92.
266. Fuselier HA, Ward DM, Lindberg JS, et al. Urinary Tamm-Horsfall protein increased after potassium citrate therapy in calcium stone formers. Urology. 1995;45:942-946.
267. Hoyer JR. Uropontin in urinary calcium stone formation. Miner Electrolyte Metab. 1995;20:385-392.
268. McKee MD, Nanci A, Khan SR. Ultrastructural immunodetection of osteopontin and osteocalcin as major matrix components of renal calculi. J Bone Miner Res. 1995;10:1913-1929.
269. Tawada T, Fujita K, Sakakura T, et al. Distribution of osteopontin and calprotectin as matrix protein in calcium-containing stone. Urol Res. 1999;27:238-242.
270. Evan AP, Coe FL, Rittling SR, et al. Apatite plaque particles in inner medulla of kidneys of calcium oxalate stone formers: osteopontin localization. Kidney Int. 2005;68:145-154.
271. Shiraga H, Min W, Van Dusen WJ, et al. Inhibition of calcium oxalate crystal growth in vitro by uropontin: another member of the aspartic acid-rich protein superfamily. PNAS. 1992;89:426-430.
272. Xie Y, Sakatsume M, Nishi S, Narita I, Arakawa M, Gejyo F. Expression, roles, receptors, and regulation of osteopontin in the kidney. Kidney Int. 2001;60:1645-1657.
273. Reinholt FP, Hultenby K, Oldberg A, Heingard D. Osteopontin - a possible anchor of osteoblasts to bone. PNAS. 1990;87:4473-4475.
274. Johnston NI, Gunasekharan VK, Ravindranath A, O'Connell C, Johnston PG, El-Tanani MK. Osteopontin as a target for cancer therapy. Front Biosci. 2008;13:4361-4372.
275. Asakura H. Osteopontin and stone formation. Int J Urol. 2002;9:108.
276. Jahnen-Dechent W, Schafer C, Ketteler M, McKee MD. Mineral chaperones: a role for fetuin-A and osteopontin in the inhibition and regression of pathologic calcification. J Mol Med. 2008;86:389-389.
277. Kleinman JG, Wesson JA, Hughes J. Osteopontin and calcium stone formation. Nephron Physiol. 2004;98:43-47.
278. Mazzali M, Kipari T, Ophascharoensuk V, Wesson JA, Johnson R, Hughes J. Osteopontin - A molecule for all seasons. QJM. 2002;95:3-13.
279. Scatena M, Liaw L, Giachelli CM. Osteopontin: a multifunctional molecule regulating chronic inflammation and vascular disease. Arterioscler Thromb Vasc Biol. 2007;27:2302-2309.
280. Nishio S, Iseda T, Takeda H, Iwata H, Yokoyama M. Inhibitory effect of calcium phosphate-associated proteins on calcium oxalate crystallization: alpha2-HS-glycoprotein, prothrombin-F1 and osteopontin. BJU Int. 2000;86:543-548.
281. Asplin JR, Arsenault D, Parks JH, Coe FL, Hoyer JR. Contribution of uropontin to inhibition of calcium oxalate crystallization. Kidney Int. 1998;53:194-199.
282. Taller A, Grohe B, Rogers KA, Goldberg HA, Hunter GK. Specific adsorption of osteopontin and synthetic polypeptides to calcium oxalate monohydrate crystals. Biophys J. 2007;93:1768-1777.
283. Wesson JA, Ganne V, Beshensky AM, Kleinman JG. Regulation by macromolecules of calcium oxalate crystal aggregation in stone formers. Urol Res. 2005;33:206-212.
284. Konya E, Umekawa T, Iguchi M, Kurita T. The role of osteopontin on calcium oxalate crystal formation. Eur Urol. 2003;43:564-571.
285. Koka RM, Huang E, Lieske JC. Adhesion of uric acid crystals to the surface of renal epithelial cells. Am J Physiol Renal Physiol. 2000;278:F989-F998.
286. Yamate T, Kohri K, Umekawa T, et al. Interaction between osteopontin on madin darby canine kidney cell membrane and calcium oxalate crystal. Utol Int. 1999;62:81-86.
287. Liu L, Chen S, Giachelli CM, Ratner BD, Jiang S. Controlling osteopontin orientation on surfaces to modulate endothelial cell adhesion. J Biomed Mater Res A. 2005;74:23-31.
288. Kleinman JG, Beshensky A, Worcester EM, Brown D. Expression of osteopontin, a urinary inhibitor of stone mineral growth, in rat kidney. Kidney Int. 1995;47:1585-1896.
289. Evan AP, Bledsoe SB, Smith SB, Bushinsky DA. Calcium oxalate crystal localization and osteopontin immunostaining in genetic hypercalciuric stone-forming rats. Kidney Int. 2004;65:154-161.
290. Khan SR, Johnson JM, Peck AB, Cornelius JG, Glenton PA. Expression of osteopontin in rat kidneys: induction during ethylene glycol induced calcium oxalate nephrolithiasis. J Urol. 2002;168:1173-1181.
291. Jiang XJ, Feng T, Chang LS, et al. Expression of osteopontin mRNA in normal and stone-forming rat kidney. Urol Res. 1998;26:389-394.
292. Kohri K, Nomura S, Kitamura Y, et al. Structure and expression of the mRNA encoding urinary stone protein (osteopontin). J Biol Chem. 1993;268:15180-15184.
293. Marengo SR, Chen DH, MacLennan GT, Resnick MI, Jacobs GH. Minipump induced hyperoxaluria and crystal deposition in rats: a model for calcium oxalate urolithiasis. J Urol. 2004;171:1304-1308.
294. Okamoto N, Aruga S, Tomita K, Takeuchi T, Kitamura T. Chronic acid ingestion promotes renal stone formation in rats treated with vitamin D3. Int J Urol. 2007;14:60-66.
295. Umekawa T, Kohri K, Kurita T, Hirota S, Nomura S, Kitamura Y. Expression of osteopontin messenger RNA in the rat kidney on experimental model of renal stone. Biochem Mol Biol Int. 1995;35:223-230.
296. Yagisawa T, Chandhoke PS, Fan J, Lucia S. Renal osteopontin expression in experimental urolithiasis. J Endourol. 1998;12:171-176.
297. Yasui T, Fujita K, Sasaki S, et al. Expression of bone matrix proteins in urolithiasis model rats. Urol Res. 1999;27:255-261.
298. Chang L, Feng T, Li J, Dou C, Wei J, Guo Y. Regulation of osteopontin expression in a rat model of urolithiasis. Chin Med J. 2001;114:829-832.
299. Iguchi M, Takamura C, Umekawa T, Kurita T, Kohri K. Inhibitory effects of female sex hormones on urinary stone formation in rats. Kidney Int. 1999;56:479-485.
300. Yagisawa T, Ito F, Osaka Y, Amano H, Kobayashi C, Toma H. The influence of sex hormones on renal osteopontin expression and urinary constituents in experimental urolithiasis. J Urol. 2001;166:1078-1082.
301. Yasui T, Sato M, Fujita K, Ito Y, Nomura S, Kohri K. Effects of allopurinol on renal stone formation and osteopontin expression in a rat urolithiasis model. Nephron. 2001;87:170-176.
302. Itoh Y, Yasui T, Okada A, Tozawa K, Hayashi Y, Kohri K. Preventive effects of green tea in renal stone formation and the role of oxidative stress in nephrolithiasis. J Urol. 2005;173:271-275.
303. Wesson JA, Johnson RJ, Mazzali M, et al. Osteopontin is a critical inhibitor of calcium oxalate crystal formation and retention in renal tubules. J Am Soc Nephrol. 2003;14:139-147.
304. Okada A, Nomura S, Higashibata Y, et al. Successful formation of calcium oxalate crystal deposition in mouse kidney by intraabdominal glyoxylate injection. aUrol Res. 2007;35:89-99.
305. Okada A, Nomura S, Saeki Y, et al. Morphological conversion of calcium oxalate crystals into stones is regulated by osteopontin in mouse kidney. J Bone Miner Res. 2008;23:1629-1637.
306. Kon S, Maeda M, Segawa T, et al. Antibodies to different peptides in osteopontin reveal complexities in the various secreted forms. J Cell Biochem. 2000;77:487-498.
307. Min W, Shiraga H, Chalko C, Goldfarb S, Krishna GG, Hoyer JR. Quantitative studies of human urinary excretion of uropontin. Kidney Int. 1998;53:189-193.
308. Nishio S, Hatanaka M, Takeda H, Iseda T, Iwata H, Yokoyama M. Analysis of urinary concentrations of calcium phosphate-associated proteins: a2-HS-glycoprotein, prothrombin F1 and osteopontin. J Am Soc Nephrol. 1999;10:S394-S396.
309. Yasui T, Fujita K, Hayashi Y, et al. Quantification of osteopontin in the urine of healthy and stone-forming men. aUrol Res. 1999;4:225-230.
310. Nishio S, Hatanaka M, Takeda H, et al. Calcium phosphate crystal-associated proteins: alpha-2-HS-glycoprotein, prothrombin fragment 1 and osteopontin. Int J Urol. 2001;8:S58-S62.
311. Huang HS, Ma MC, Chen CF, Chen J. Lipid peroxidation and its correlations with urinary levels of oxalate, citric acid, and osteopontin in patients with renal calcium oxalate stones. Urology. 2003;62:1123-1128.
312. Tsuji H, Tohru U, Hirotsugu U, Masanori I, Yuji H, Takashi K. Urinary concentration of osteopontin and association with urinary supersaturation and crystal formation. Int J Urol. 2007;14:630-634.
313. Hedgepeth RC, Yang L, Resnick MI, Marengo SR. Expression of proteins that inhibit calcium oxalate crystallization in vitro in the urine of normal and stone-forming individuals. Am J Kidney Dis. 2001;37:104-112.
314. Thurgood LA, Grover PK, Ryall RL. High calcium concentration and calcium oxalate crystals cause significant inaccuracies in the measurement of urinary osteopontin by enzyme linked immunosorbent assay. Urol Res. 2008;36:103-110.
315. Lian JB, Prien EL, Glimcher MJ, Gallop PM. The presence of protein-bound gamma-carboxylic acid in calcium-containing renal calculi. J Clin Invest. 1977;59:1151-1157.
316. Suzuki K, Moriyama M, Nakajima C, et al. Isolation and partial characterization of crystal matrix protein as a potent inhibitor of calcium oxalate crystal aggregation: evidence of activation peptide of human prothrombin. Urol Res. 1994;22:45-50.
317. Stapleton A M F, Dawson CJ, Grover PK, et al. Further evidence linking urolithiasis and blood coagulation: Urinary prothrombin fragment 1 is present in stone matrix. Kidney Int. 1996;49:880-888.
318. Stapleton A M F, Seymour AE, Brennan JS, Doyle IR, Marshall VR, Ryall RL. The immunohistochemical distribution and quantification of crystal matrix protein. Kidney Int. 1993;44:817-824.
319. Stapleton A M F, Timme TL, Ryall RL. Gene expression of prothrombin in the human kidney and its potential relevance to kidney stone disease. Br J Urol. 1998;81:666-672.
320. Suzuki K, Tanaka T, Miyazawa K, et al. Gene expression of prothrombin in human and rat kidneys: Basic and clinical approach. J Am Soc Nephrol. 1999;10:S408-S411.
321. Grover PK, Stapleton A M F, Ryall RL. Prothrombin gene expression in rat kidneys provides an opportunity to examine its role in urinary stone pathogenesis. J Am Soc Nephrol. 1999;10:S404-S407.
322. Grover PK, Dogra SC, Davidson BP, Stapleton A M F, Ryall RL. The prothrombin gene is expressed in the rat kidney. Implications for urolithiasis research. Eur J Biochem. 2000;267:61-67.
323. Grover PK, Ryall RL. Inhibition of calcium oxalate crystal growth and aggregation by prothrombin and its fragment in vitro. Relationship between protein structure and inhibitory activity. Eur J Biochem. 1999;263:50-56.
324. Ryall RL, Grover PK, Stapleton A M F, et al. The urinary F1 activation peptide of human prothrombin is a potent inhibitor of calcium oxalate crystallization in undiluted human urine in vitro. Clin Sci. 1995;89:533-541.
325. Grover PK, Ryall RL. Inhibition of calcium oxalate crystal growth and aggregation by prothrombin and its activation fragments in undiluted human urine in vitro: Relationship between protein structure and inhibitory activity. Clin Sci. 2002;102:425-434.
326. Buchholz NP, Kim DS, Grover PK, Dawson CJ, Ryall RL. The effect of warfarin therapy on the charge properties of urinary prothrombin fragment 1 and crystallization of calcium oxalate in undiluted human urine. J Bone Miner Res. 1999;14:1003-1012.
327. Liu J, Wang T, Chen J, Wang S, Ye Z. Decreased inhibitory activity of prothrombin to calcium oxalate crystallization by specific chemical modification of its gamma-carboxyglutamic acid residues. Urology. 2006;67:201-203.
328. Liu J, Chen J, Wang T, Wang S, Ye Z. Effects of urinary prothrombin fragment 1 in the formation of calcium oxalate calculus. J Urol. 2005;173:113-116.
329. Webber D, Radcliffe CM, Royle L, et al. Sialylation of urinary prothrombin fragment 1 is implicated as a contributory factor in the risk of calcium oxalate kidney stone formation. FEBS J. 2006;273:3024-3037.
330. Webber D, Rodgers AL, Sturrock ED. Glycosylation of prothrombin fragment 1 governs calcium oxalate crystal nucleation and aggregation, but not crystal growth. Urol Res. 2007;35:277-285.
331. Webber D, Rodgers AL, Sturrock ED. Synergism between urinary prothrombin fragment 1 and urine: a comparison of inhibitory activities in stone-prone and stone-free population groups. Clin Chem Lab Med. 2002;40:930-936.
332. Durrbaum D, Rodgers AL, Sturrock ED. A study of crystal matrix extract and urinary prothrombin fragment 1 from a stone-prone and stone-free population. Urol Res. 2001;29:83-88.
333. Gul A, Rez P. Models for protein binding to calcium oxalate surfaces. Urol Res. 2007;35:63-71.
334. Moriyama MT, Domiki C, Miyazawa K, Tanaka T, Suzuki K. Effects of oxalate exposure on Madin-Darby canine kidney cells in culture: renal prothrombin fragment-1 mRNA expression. Urol Res. 2005;33:470-475.
335. Grover PK, Miyazawa K, Coleman M, Stahl J, Ryall RL. Renal prothrombin mRNA is significantly decreased in a hyperoxaluric rat model of nephrolithiasis. aJ Pathol. 2006;210:273-281.
336. Dean CJ, Macardle PJ, Ryall RL. The effect of the presence of calcium oxalate crystals on the measurement of prothrombin fragment 1 in urine. in: Rodgers AL, Hibbert BE, Hess B, Khan SR, Preminger GM, eds. Urolithiasis 2000. Cape Town: University of Cape Town; 2000:150-152.
337. Sørensen S, Hansen K, Bak S, Justesen SJ. An unidentified macromolecular inhibitory constituent of calcium oxalate crystal growth in human urine. Urol Res. 1990;18:373-379.
338. Zhuo L, Hascall VC, Kimata K. Inter-a-trypsin inhibitor, a covalent protein-glycosaminoglycan-protein complex. J Biol Chem. 2004;279:38079-28082.
339. Evan AP, Bledsoe S, Worcester EM, Coe FL, Lingeman JE, Bergsland KJ. Renal inter-alpha-trypsin inhibitor heavy chain 3 increases in calcium oxalate stone-forming patients. Kidney Int. 2007;72:1503-1511.
340. Fries E, Blom AM. Bikunin - not just a plasma proteinase inhibitor. aInt J Biochem Cell Biol. 2000;32:125-137.
341. Atmani F, Lacour B, Drueke T, Daudon M. Isolation and purification of a new glycoprotein from human urine inhibiting calcium oxalate crystallization. aUrol Res. 1993;21:6.
342. Atmani F, Lacour B, Strecker G, Parvy P, Drueke T, Daudon M. Molecular characteristics of uronic-acid-rich protein, a strong inhibitor of calcium oxalate crystallization in vitro. Biochem Biophys Res Commun. 1993;91:1158-1165.
343. Atmani F, Mizon J, Khan SR. Identification of uronic-acid-rich protein as urinary bikunin, a light chain of inter-a-trypsin inhibitor. Eur J Biochem. 1996;236:984-990.
344. Dawson CJ, Grover PK, Ryall RL. Inter-a-inhibitor in urine and calcium oxalate urinary crystals. Br J Urol. 1998;81:20-26.
345. Atmani F, Opalko FJ, Khan SR. Association of urinary macromolecules with calcium oxalate crystals induced in vitro in normal human and rat urine. Urol Res. 1996;24:45-50.
346. Dawson CJ, Grover PK, Kanellos J, Pham H, Kupczyk OA, Ryall RL. Inter-a-inhibitor in calcium stones. Clin Sci. 1998;95:187-193.
347. Atmani F, Khan SR. Role of urinary bikunin in the inhibition of calcium oxalate crystallization. aJ Am Soc Nephrol Suppl. 1999;14:S385-8.
348. Atmani F, Lacour B, Jungers P, Drueke T, Daudon M. Reduced inhibitory activity of uronic-acid-rich protein (UAP) in the urine of stone formers. Urol Res. 1994;22:257-260.
349. Dean CJ, Kanellos J, Pham H, et al. The effect of inter-a-inhibitor and several of its derivatives on calcium oxalate crystallization in vitro. Clin Sci. 2000;98:471-480.
350. Kobayashi H, Shibata K, Fujie M, Sugino D, Terao T. Identification of structural domains in inter-a-trypsin inhibitor involved in calcium oxalate crystallization. Kidney Int. 1998;53:1727-1735.
351. Medetognon-Benisson J, Tardivel S, Hennequin C, Daudon M, Drueke T, Lacour B. Inhibitory effect of bikunin on calcium oxalate crystallization in vitro and urinary bikunin decrease in renal stone formers. Urol Res. 1999;27:69-75.
352. Okuyama M, Yamaguchi S, Yachiku S. Identification of bikunin isolated from human urine inhibits calcium oxalate crystal growth and its localization in the kidneys. Int J Urol. 2003;10:530-5.
353. Atmani F, Khan SR. Characterization of uronic-acid-rich inhibitor of calcium oxalate crystallization isolated from rat urine. Urol Res. 1995;23:95-101.
354. Atmani F, Glenton PA, Khan SR. Role of inter-alpha-inhibitor and its related proteins in experimentally induced calcium oxalate urolithiasis. Localization of proteins and expression of bikunin gene in the rat kidney. Urol Res. 1999;27:63-67.
355. Iida S, Peck AB, Johnson-Tardieu J, et al. Temporal changes in mRNA expression for bikunin in the kidneys of rats during calcium oxalate nephrolithiasis. J Am Soc Nephrol. 1999;10:986-996.
356. Moriyama MT, Glenton PA, Khan SR. Expression of inter-alpha inhibitor related proteins in kidneys and urine of hyperoxaluric rats. J Urol. 2001;165:1687-1692.
357. Eguchi Y, Inoue M, Iida S, Matsuoka K, Noda S. Heparan sulphate (HS)/heparan sulfate proteoglycan (HSPG) and bikunin are upgraded during calcium oxalate nephrolithiasis in rat Kidney. Kurume Med. 2002;49:99-107.
358. Iida S, Peck AB, Byer KJ, Khan SR. Expression of bikunin mRNA in renal epithelial cells after oxalate exposure. J Urol. 1999;162:1480-1486.
359. Marengo SR, Resnick MI, Yang L, Chung JY. Differential expression of urinary inter-a-trypsin inhibitor trimers and dimers in normal compared to active calcium oxalate stone forming men. J Urol. 1998;159:1444-1450.
360. Suzuki M, Kobayashi H, Kageyama S, Shibata K, Fujie M, Terao T. Excretion of bikunin and its fragments in the urine of patients with renal stones. J Urol. 2001;166:268-274.
361. Stnz I, Trabichavsky I. Calprotectin - a pleiotropic molecule in acute and chronic inflammation. Physiol Res. 2004;53:245-253.
362. Bennet J, Dretler SP, Selengut J, Orme-Johnson WH. Identification of the calcium-binding protein calgranulin in the matrix of struvite stones. J Endourol. 1994;8:95-98.
363. Umekawa T, Kurita T. Calprotecin-like protein is related to soluble organic matrix in calcium oxalate urinary stone. Biochem Mol Biol Int. 1994;34:309-313.
364. Sakakura T, Fujita K, Yasui T, et al. Calcium phosphate stones produced by Madin-Darby canine kidney (MDCK) cells inoculated in nude mice. Urol Res. 1999;27:200-205.
365. Pillay SN, Asplin JR, Coe FL. Evidence that calgranulin is produced by kidney cells and is an inhibitor of calcium oxalate crystallization. Am J Physiol. 1998;275:F255-F261.
366. Bergsland KJ, Kelly JK, Coe BJ, Coe FL. Urine protein markers distinguish stone-forming from non-stone-forming relatives of calcium stone formers. Am J Physiol Renal Physiol. 2006;291:F530-F536.
367. Boyce WH, King J, Fielden M. Total non-dialyzable solids (TNDS) in human urine XIII. Immunological detection of a component peculiar to renal calculous matrix and to urine of calculous patients. J Clin Invest. 1962;41:1180-1189.
368. Dussol B, Geider S, Lilova A, et al. Analysis of the soluble matrix of five morphologically different kidney stones. Urol Res. 1995;23:45-51.
369. Cerini C, Geider S, Dussol B, et al. Nucleation of calcium oxalate
370. Edyvane KA, Ryall RL, Marshall VR. The influence of serum and serum proteins on calcium oxalate crystal growth and aggregation. Clin Chim Acta. 1986;157:81-88.
371. Honda M, Yoshioka T, Yamaguchi S, et al. Characterization of protein components of human urinary crystal surface binding substance. Urol Res. 1997;25:355-360.
372. Hess B, Meinhardt U, Zipperle L, Giovanoli R, Jaeger P. Simultaneous measurements of calcium oxalate crystal nucleation and aggregation: impact of various modifiers. Urol Res. 1995;23:231-238.
373. Chen WC, Lin HS, Chen HY, Shih CH, Li CW. Effects of TammHorsfall protein and albumin on calcium oxalate crystallization and importance of sialic acids. Mol Urol. 2001;5:1-5.
374. Wu W, Gerard DE, Nancollas GH. Nucleation at surfaces: the importance of interfacial energy. J Am Soc Nephrol Suppl. 1999;14:S355-S358.
375. Pankov R, Yamada KM. Fibronectin at a glance. J Cell Sci. 2002;115:3861-3863.
376. Tsujihata M, Miyake O, Yoshimura K, Kakimoto KI, Takahara S, Okuyama A. Fibronectin as a potent inhibitor of calcium oxalate urolithiasis. J Urol. 2000;164:1718-1723.
377. Tsujihata M, Miyake O, Yoshimura K, Tsujikawa K, Tei N, Okuyama A. Renal tubular injury and fibronectin. Urol Res. 2003;31:368-373.
378. Tsujihata M, Miyake O, Yoshimura K, Kakimoto K, Takahara S, Okuyama A. Comparison of fibronectin content in urinary macromolecules between normal subjects and recurrent stone formers. Eur Urol. 2001;40:458-462.
379. Ryall RL. Chaos, crystals and calculi. In: Jungers P, Daudon M, eds. Renal Stone Disease. Crystallization Process, Pathophysiology, Metabolic Disorders and Prevention. Paris: Elsevier; 1997:113-117.